## HANAA ABDEL-MAGUID

Mobile: +2 0100 898 6775 / +2 0114 114 9077

Website: <a href="www.pharco.org">www.pharco.org</a> Email: <a href="hanaa@eepi-pharco.org">hanaa@eepi-pharco.org</a>



## **CAREER OVERVIEW**

I am a pharmaceutical management professional with 8 years' experience in the pharmaceutical sales and marketing, 1.5 years' experience in administrative corporate management, 4.5 years' experience in the research and development innovation project management and I was recently assigned as Medical Director. I have worked in multinational and Egyptian pharmaceutical companies. I have a proven track record of developing new business and motivating cross-functional teams to consistently achieve action plans. I've completed a Doctorate of Business Administration with distinction and I am now seeking a new professional challenge.

## **Presentation Title:**

The results of the clinical trial entitled: A Phase II b/ III a, Randomized Study to Evaluate the Efficacy and Safety of PPI 668 "Ravidasvir" (NS5A inhibitor) plus Sofosbuvir, with or without Ribavirin, in Patients with Chronic Hepatitis C Genotype-4

## CAREER HISTORY

March 2015 - Present: Medical Director

European Egyptian Pharmaceutical Industries (EEPI) - Pharco Corporation, Egypt

July 2013 - Present: R&D Innovation Projects Head

**Pharco Corporation, Egypt** 

June 2010 – June 2013: R&D Innovation Projects Manager

Pharco Corporation, Egypt

Pharco Corporation is a group of pharmaceutical companies the first of which is Pharco Pharmaceuticals that was established in 1982. Its principal activity consists of discovering, developing, manufacturing, and marketing medicines. It is located in Alexandria, Egypt. It is one of the main players in the market of Egyptian Pharmaceutical Industry. The R&D orientation of Pharco Corporation lead to having three innovative products in the market, and a number of innovation projects in the pipeline.